Publications

BRAF Nov 10 2025 Plixorafenib (PLX8394/FORE8394) treatment leads to sustained tumor regression in preclinical models of BRAF-mutated primary and brain metastatic melanoma Read more

BRAF Sep 16 2025 Clinical Activity and Safety of Novel BRAF Inhibitor Plixorafenib (FORE8394; PLX8394) in Advanced TC Harboring BRAF Alterations Read more

BRAF Sep 16 2025 Effect of Food & Cobicistat Administration on the Pharmacokinetics & Safety of Plixorafenib in Healthy Participants Read more

BRAF May 31 2025 FORTE: A phase 2 Master Protocol Assessing Plixorafenib for BRAF-Altered Cancers Read more

BRAF Apr 25 2025 Circulating tumor DNA analysis in patients with BRAF-mutated advanced unresectable solid tumors treated with plixorafenib (FORE8394/PLX8394) in Phase 1/2a study Read more

BRAF Apr 25 2025 FORTE: A Phase 2 Master Protocol Assessing Plixorafenib for BRAF-Altered Cancers Read more

BRAF Oct 21 2024 Activity of BRAF Inhibitor Plixorafenib (FORE8394) in Advanced Ovarian Cancer Harboring BRAF V600E Mutation Read more

BRAF Oct 17 2024 Safety & Efficacy of BRAF Inhibitor Plixorafenib in Children & Adults with Recurrent, BRAF altered PCNSTs Read more

BRAF Apr 17 2024 Paradox-Breaker BRAF inhibitor plixorafenib (FORE8394) synergizes with MEKi in BRAF V600 and non- V600 alterations Read more

BRAF Apr 17 2024 Efficacy of BRAF Inhibitor Plixorafenib (FORE8394) in Recurrent PCNST Read more